LAG3 and cancer: Additionally, several other novel treatment strategies with promising preclinical results are undergoing corresponding clinical investigations, such as chimeric antigen receptor (CAR) based therapies [18–20], cancer vaccines [21, 22], and novel ICIs (anti-T cell immunoglobulin and mucin domain-containing protein 3 (TIM3), anti-T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT), anti-lymphocyte activation gene 3 (LAG3), anti‐CTLA4-LAG‐3 antibodies, etc.)[23–29].